A concise history of gout and hyperuricemia and their treatment

Arthritis Research and Therapy

Volumn 8, Issue SUPPL. 1, 2006, Pages

  Nuki, George ^a   Simkin, Peter A ^b  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIGOUT AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; AZATHIOPRINE; BENZBROMARONE; COLCHICINE; COLCHICUM AUTUMNALE EXTRACT; COLCHICUM EXTRACT; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; FEBUXOSTAT; FENOFIBRATE; LOSARTAN; NONSTEROID ANTIINFLAMMATORY AGENT; OXIPURINOL; PROBENECID; SALICYLIC ACID DERIVATIVE; SULFINPYRAZONE; UNCLASSIFIED DRUG; URATE; URATE OXIDASE; URICOSURIC AGENT; XANTHINE OXIDASE INHIBITOR; URIC ACID;

ALCOHOL CONSUMPTION; ARTHRALGIA; ARTHRITIS; CLINICAL TRIAL; COLCHICUM; COLCHICUM AUTUMNALE; DIET THERAPY; DRUG DOSE REGIMEN; DRUG HALF LIFE; FOOD INTAKE; GOUT; HUMAN; HYPERURICEMIA; LIFESTYLE; METATARSOPHALANGEAL JOINT; NONHUMAN; REVIEW; UNSPECIFIED SIDE EFFECT; URIC ACID BLOOD LEVEL; URIC ACID URINE LEVEL; HISTORY; METABOLISM; PATHOPHYSIOLOGY; POLITICS; UNITED STATES;

ARTHRITIS, GOUTY; GOUT; HISTORY, 19TH CENTURY; HISTORY, ANCIENT; HUMANS; HYPERURICEMIA; POLITICS; UNITED STATES; URIC ACID;

EID: 33745226185     PISSN: 14786354     EISSN: None     Source Type: Journal    
DOI: 10.1186/ar1906     Document Type: Review

References (43)

1. Schwartz S: Disease of distinction. [http://www.stephanaschwartz.com/PDF/ disease_of_distinction.pdf.]
2. Hippocrates: The Genuine Works of Hippocrates, vol I and II. Translated and edited by Adams F. New York: Wood; 1886.
3. Galen C: Claudii Galeni Opera Omni. Leipzig: CG Kühn; 1821-1833.
4. Garrison FH: An Introduction to the History of Medicine. Philadelphia, PA: Saunders; 1929.
5. Copeman WSC: A Short History of the Gout and the Rheumatic Diseases. Los Angeles, CA: University of California Press; 1964.
6. Sydenham T: Tractatus de Podagra et Hydrope. London: G Kettilby; 1683.
7. Lewis WS (editor): Horace Walpole to Sir Horace Mann, 8 May 1873. In The Yale Editions of Horace Walpole's Correspondence, vol 25. New Haven: Yale University Press; 1937-1983:402.
8. Zollner N: Influence of various purines on uric acid metabolism. Bibl Nutr Dieta 1973, 19:34-43.
9. Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G: Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med 2004, 350:1093-1103.
10. McCarty DJ: A historical note: Leeuwenhoek's description of crystals from a gouty tophus. Arthritis Rheum 1970, 13:414-418.
11. Stukeley W: Of the Gout. London: Roberts; 1734.
12. Scheele KW: Examen chemicum calculi urinarii. Opuscula 1776, 2:73.
13. Woolaston WH: On gouty and urinary concretions. Philosoph Trans R Soc Lond 1787, 87:386-415.
14. Garrod AB: Observations on certain pathological conditions of the blood and urine in gout, rheumatism and Bright's disease. Trans M-Chir Soc Edinburgh 1848, 31:83-97.
15. Garrod AB: The Nature and Treatment of Gout and Rheumatic Gout. London: Walton and Maberly; 1859.
16. Freudweiler M: Experimentelle untersuchungen uber das wesen der gichtknoten. Dtsch Arch Klin Med 1899, 63:266-335.
17. His WJ: Schicksal und wirkungendes sauren harnsauren natrons in bauch und gelenkhohle das kaninchens. Dtsch Arch Klin Med 1900, 67:81-108.
18. McCarty DJ, Hollander JL: Identification of urate crystals in gouty synovial fluid. Ann Intern Med 1961, 54:452-460.
19. McCarty DJ Jr, Kohn NN, Faires JS: The significance of calcium phosphate crystals in the synovial fluid of arthritic patients: the 'pseudogout syndrome'. I. Clinical aspects. Ann Intern Med 1962, 56:711-737.
20. Arataeus the Cappadocian: The Extant Works. Translated and edited by Adams F. London: The Sydenham Society; 1856.
21. Garrod AE: The Inborn Factors in Disease: An Essay. London: Oxford University Press; 1931.
22. Seegmiller JE, Rosenbloom FM, Kelley WN: An enzyme defect associated with a sex-linked human neurologigacal disorder and excessive purine synthesis. Science 1967, 155:1682-1684.
23. Seegmiller JE, Grayzel AI, Laster L, Liddle L: Uric acid production in gout. J Clin Invest 1961, 40:1304-1314.
24. Stoerk A: An Essay on the Use and Effects of the Root of the Colchicum autumnale, or Meadow Saffron, Translated from the Latin. London: T Becket and PA de Honet; 1764.
25. Terkeltaub RA: Clinical Practice. Gout. N Engl J Med 2003, 349: 1647-1655.
26. Garrod AB: A Treatise on Gout and Rheumatic Gout (Rheumatoid Arthritis). 3rd ed. London: Longmans, Green; 1876.
27. Haig A: A contribution to the pathology of high arterial tension, headache, epilepsy, mental depression, gout, rheumatism, diabetes, Bright's disease, and other disorders. In Uric Acid as a Factor in the Causation of Disease. vol 12, 7th ed. London: J & A Churchill; 1908:940.
28. Griebsch A, Kaiser W: Einfluss exogener purine auf den harnsaurestoffwechsel. In Handbuch der Inneren Medizin Bd 7, 5, aufl. Berlin: Springer; 1976.
29. Kippen I, Whitehouse MW, Klinenberg JR: Pharmacology of uricosuric drugs. Ann Rheum Dis 1974, 33:391-396.
30. See G: Etudes sur l'acid salicylique et les salicylates: traitement du rhumatisme aigu et chronique, de la goutte, et de diverses affections du system nerveux sensitive par les salicylates. Bull Acad Med Paris 1877, 6:689-706, 717-754, 926-933, 937-943, 1024-1027.
31. Yu T-F, Gutman AB: Study of the paradoxical effects of salicylate in low, intermediate and high dosage on the renal mechanisms for excretion of urate in man. J Clin Invest 1959, 38: 1298-1315.
32. Talbott JH, Bishop C, Norcross M, Lockie LM: The clinical and metabolic effects of benemid in patients with gout. Trans Assoc Am Physicians 1951, 64:372.
33. Burns JJ, Yu T-F, Ritterband A, Perel JM, Gutman AB, Brodie BB: A potent new uricosuric agent, the sulfoxide metabolite of the phenylbutazone analogue G-25671. J Pharmacol Exp Ther 1957, 119:418-426.
34. Delbarre F, Auscher C, Amor B: Action uricosurique de certains derives du benzofuranne. Soc Med Hop Paris 1965, 116:1193-1196.
35. Kamper AL, Nielsen AH: Uricosuric effect of losartan in patients with renal transplants. Transplantation 2001, 72:671-674.
36. Feher MD, Hepburn AL, Hogarth MB, Ball SG, Kaye SA: Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricaemia and gout. Rheumatology 2003, 42: 321-325.
37. London M, Hudson PB: Uricolytic activity of purified uricase in two human beings. Science 1957, 125:937-938.
38. Bosly A, Sonet A, Pinkerton CR, McCowage G, Bron D, Sanz MA, Van den Berg H: Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study. Cancer 2003, 98:1048-1054.
39. Rundles RW, Wyngaarden JB, Hitchings GH, Elion GB, Silberman HR: Effects of a xanthine oxidase inhibitor on thiopurine metabolism, hyperuricaemia and gout. Trans Assoc Am Physicians 1963, 76:126-140.
40. Walter-Sack I, de Vries JX, Kutschker C, Ittensohn A, Voss A: Disposition and uric acid lowering effect of oxipurinol: comparison of different oxipurinol formulations and allopurinol in healthy individuals. Eur J Clin Pharmacol 1995, 49:215-220.
41. Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Palo WA, Eustace D, Vernillet L, Joseph-Ridge N: Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a 28-day, multicenter, phase II, randomized, double-blind, placebo-controlled dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum 2005, 52:916-923.
42. Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, Streit J, Joseph-Ridge N: Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005, 353:2450-2461.
43. Constitution of the United States: a history. [http://www.archives.gov/ national-archives-experience/charters/constitution_history.html]